Company & Sponsor Intelligence
National Neuroscience Institute
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting1
Completed1
Countries1
Therapeutic footprint
alzheimersneuro_oncologyout_of_scopeparkinsons
Indexed studies
NCT02444637Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
alzheimers · SingaporePHASE4
alzheimers · SingaporePHASE4
NCT05824546uSINE-PAMS Artificial Intelligence Driven, Ultrasound-Guided Lumbar Puncture to Improve Procedural Accuracy
out_of_scope · SingaporeNA
out_of_scope · SingaporeNA
NCT04491383Tocotrienols in Parkinson's Disease (PD)
parkinsons · SingaporePHASE2
parkinsons · SingaporePHASE2
NCT06894225Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
neuro_oncology · SingaporePHASE2
neuro_oncology · SingaporePHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →